Epoch Investment Partners Has Upped By $1.71 Million Its Schein Henry (HSIC) Position; Last Week PAREXEL International (PRXL) Analysts

September 17, 2017 - By Vivian Park

Epoch Investment Partners Inc increased Schein Henry Inc (HSIC) stake by 41.97% reported in 2016Q4 SEC filing. Epoch Investment Partners Inc acquired 11,307 shares as Schein Henry Inc (HSIC)’s stock rose 5.77%. The Epoch Investment Partners Inc holds 38,249 shares with $5.80 million value, up from 26,942 last quarter. Schein Henry Inc now has $13.10B valuation. The stock increased 2.86% or $2.31 on September 15, reaching $82.88. About 2.92 million shares traded or 104.20% up from the average. Henry Schein, Inc. (NASDAQ:HSIC) has risen 4.05% since September 17, 2016 and is uptrending. It has underperformed by 12.65% the S&P500.

Among 17 analysts covering Parexel International (NASDAQ:PRXL), 1 have Buy rating, 3 Sell and 13 Hold. Therefore 6% are positive. Parexel International had 38 analyst reports since August 7, 2015 according to SRatingsIntel. The stock of PAREXEL International Corporation (NASDAQ:PRXL) has “Mkt Underperform” rating given on Monday, January 25 by Avondale. Deutsche Bank downgraded the stock to “Sell” rating in Friday, February 3 report. SunTrust upgraded the stock to “Buy” rating in Monday, March 28 report. The company was downgraded on Monday, February 6 by Credit Suisse. The stock of PAREXEL International Corporation (NASDAQ:PRXL) earned “Hold” rating by Evercore on Tuesday, June 20. The firm has “Hold” rating by Jefferies given on Tuesday, June 6. Avondale maintained PAREXEL International Corporation (NASDAQ:PRXL) on Monday, April 11 with “Underperform” rating. The firm has “Hold” rating by Jefferies given on Tuesday, June 20. The stock of PAREXEL International Corporation (NASDAQ:PRXL) earned “Hold” rating by Barclays Capital on Tuesday, June 20. The stock has “Equal-Weight” rating by First Analysis on Thursday, November 17. See PAREXEL International Corporation (NASDAQ:PRXL) latest ratings:

11/09/2017 Broker: Jefferies Rating: Hold New Target: $88.1 Maintain
21/07/2017 Broker: Jefferies Rating: Hold New Target: $88.1000 Maintain
20/06/2017 Broker: Jefferies Rating: Hold New Target: $88.1000 Maintain
20/06/2017 Broker: Barclays Capital Rating: Hold Downgrade
20/06/2017 Broker: Evercore Rating: Hold Downgrade
06/06/2017 Broker: Jefferies Rating: Hold New Target: $66.0000 Maintain
06/06/2017 Broker: Credit Suisse Rating: Hold New Target: $83.0000
30/05/2017 Broker: Mizuho Rating: Buy New Target: $75.0000 Maintain
23/05/2017 Broker: Goldman Sachs Old Rating: Sell New Rating: Neutral Upgrade
15/05/2017 Broker: Evercore Old Rating: Hold New Rating: Outperform Upgrade

Among 17 analysts covering Henry Schein Inc. (NASDAQ:HSIC), 8 have Buy rating, 0 Sell and 9 Hold. Therefore 47% are positive. Henry Schein Inc. had 25 analyst reports since July 31, 2015 according to SRatingsIntel. RBC Capital Markets maintained Henry Schein, Inc. (NASDAQ:HSIC) rating on Thursday, November 5. RBC Capital Markets has “Outperform” rating and $170 target. UBS maintained Henry Schein, Inc. (NASDAQ:HSIC) rating on Friday, September 15. UBS has “Buy” rating and $204.0 target. The firm has “Hold” rating by Gabelli given on Friday, November 6. The rating was upgraded by Goldman Sachs to “Buy” on Tuesday, October 11. The firm earned “Neutral” rating on Tuesday, December 6 by Northcoast. The firm earned “Buy” rating on Tuesday, January 10 by Gabelli. The rating was upgraded by PiperJaffray on Friday, September 15 to “Overweight”. The firm has “Buy” rating given on Thursday, October 6 by UBS. The stock has “Outperform” rating by Robert W. Baird on Tuesday, January 3. The rating was maintained by Jefferies with “Hold” on Tuesday, August 22.

Epoch Investment Partners Inc decreased Cvs Health Corp (NYSE:CVS) stake by 1.72 million shares to 21,711 valued at $1.71M in 2016Q4. It also reduced Us Ecology Inc (NASDAQ:ECOL) stake by 66,145 shares and now owns 527,845 shares. National Instrs Corp (NASDAQ:NATI) was reduced too.

Since March 17, 2017, it had 0 insider buys, and 3 sales for $5.09 million activity. RACIOPPI MICHAEL sold $1.71M worth of stock or 9,969 shares. $950,478 worth of stock was sold by MLOTEK MARK E on Friday, March 17. Another trade for 7,338 shares valued at $1.29M was made by Minowitz Robert on Friday, May 12. 9,300 Henry Schein, Inc. (NASDAQ:HSIC) shares with value of $1.60 million were sold by McGlynn Lorelei. $2.20M worth of Henry Schein, Inc. (NASDAQ:HSIC) was sold by BENJAMIN GERALD A on Thursday, May 11.

Investors sentiment increased to 1.16 in Q4 2016. Its up 0.25, from 0.91 in 2016Q3. It is positive, as 50 investors sold HSIC shares while 192 reduced holdings. 70 funds opened positions while 127 raised stakes. 71.97 million shares or 0.99% more from 71.27 million shares in 2016Q3 were reported. Gsa Cap Llp has invested 0.08% in Henry Schein, Inc. (NASDAQ:HSIC). Victory Management has 7,856 shares for 0% of their portfolio. Reilly Herbert Faulkner Iii invested in 21,100 shares. Moreover, Schwab Charles Investment Management Incorporated has 0.04% invested in Henry Schein, Inc. (NASDAQ:HSIC) for 246,499 shares. 28,051 are held by Stifel Financial. Bartlett Co Lc has invested 0.01% of its portfolio in Henry Schein, Inc. (NASDAQ:HSIC). Dekabank Deutsche Girozentrale accumulated 48,325 shares. Pitcairn has 1,997 shares. 1,485 are held by Advisor Prtnrs Ltd Liability Com. Lombard Odier Asset Mngmt (Europe) Limited has invested 0.08% in Henry Schein, Inc. (NASDAQ:HSIC). Proshare Lc holds 0.05% of its portfolio in Henry Schein, Inc. (NASDAQ:HSIC) for 26,961 shares. Zurcher Kantonalbank (Zurich Cantonalbank) owns 0.03% invested in Henry Schein, Inc. (NASDAQ:HSIC) for 17,078 shares. Kelly Lawrence W Ca reported 0.01% in Henry Schein, Inc. (NASDAQ:HSIC). First Manhattan has invested 0% of its portfolio in Henry Schein, Inc. (NASDAQ:HSIC). Ameriprise Financial invested in 0.02% or 244,936 shares.

PAREXEL International Corporation is a biopharmaceutical outsourcing services company. The company has market cap of $4.50 billion. The Firm provides a range of expertise in clinical research, clinical logistics, medical communications, consulting, commercialization, and technology services and products to pharmaceutical, biotechnology and medical device industries. It has a 42.82 P/E ratio. The Company’s divisions include Clinical Research Services (CRS), PAREXEL Consulting Services (PC) and PAREXEL Informatics (PI).

Investors sentiment decreased to 0.75 in Q4 2016. Its down 0.19, from 0.94 in 2016Q3. It worsened, as 51 investors sold PAREXEL International Corporation shares while 100 reduced holdings. 46 funds opened positions while 83 raised stakes. 47.26 million shares or 0.12% more from 47.20 million shares in 2016Q3 were reported. Gotham Asset Management Ltd Llc has invested 0.1% in PAREXEL International Corporation (NASDAQ:PRXL). State Treasurer State Of Michigan holds 0.01% or 21,500 shares. Oxford Asset Mngmt reported 161,845 shares. Sheets Smith Wealth Mngmt invested in 0.1% or 5,157 shares. Tci Wealth Inc invested in 0.01% or 278 shares. The Connecticut-based Cubist Systematic Strategies Ltd Com has invested 0.06% in PAREXEL International Corporation (NASDAQ:PRXL). Sterling Cap Management Ltd reported 493,893 shares. Shelton Management holds 18,507 shares. Adams Diversified Equity Fund Inc holds 12,976 shares. Tealwood Asset Mgmt Inc reported 28,465 shares. Manufacturers Life Ins The has invested 0.04% in PAREXEL International Corporation (NASDAQ:PRXL). Ny State Common Retirement Fund, New York-based fund reported 77,657 shares. 16,089 are held by Zebra Capital Mgmt Ltd Liability Corporation. Engaged Capital Lc has 92,327 shares. Aqr Cap Mngmt Ltd Liability reported 0.02% in PAREXEL International Corporation (NASDAQ:PRXL).

The stock increased 0.02% or $0.02 on September 15, reaching $87.95. About 798,422 shares traded or 13.22% up from the average. PAREXEL International Corporation (NASDAQ:PRXL) has risen 35.35% since September 17, 2016 and is uptrending. It has outperformed by 18.65% the S&P500.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Twitter Auto Publish Powered By : XYZScripts.com